🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInsurance & AccessCost comparison: brand vs compounded — comprehensive analysis

Cost comparison: brand vs compounded — comprehensive analysis

DataDave Sun, Jun 7, 2026 at 4:17 AM 8 replies 299 viewsPage 1 of 2
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Jun 7, 2026 at 4:17 AM#1

Writing this once so I can stop repeating it across threads. It is about compounded supply, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

The condition it depends on

The enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

The practical version

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

What I am not sure about

The question I want answered is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

— DataDave · corrections welcome and will be edited into this post with credit
49 19VendorMark, COA_Karl, MikeFit_NJ and 46 others
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Jun 7, 2026 at 4:57 AM#2
DataDave said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

DataDave has the substance of this right. The condition it depends on is worth stating. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Last edited: Jun 7, 2026 at 5:57 AM
48 18PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 45 others
Reply Quote Save Share Report
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Jun 7, 2026 at 5:38 AM#3
DataDave said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

47 17Dr.EndoIndy, tom_AK, josh_phd_bmore and 44 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jun 7, 2026 at 6:18 AM#4

Short answer first, then the reasoning. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

I would rather be corrected than agreed with, if it comes to it.

46 16DoseLogDan, SleepFixSam, PurityPaulOR and 43 others
Reply Quote Save Share Report
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Jun 7, 2026 at 10:12 AM#5
JennaRN said:
They are two different exemptions from the same federal requirements and they buy different things.

Agreed, and coverage criteria are plan-specific rather than insurer-specific. Two people with the same insurer and different employers have different rules, which is why "my insurer covers it" is not transferable information.

Last edited: Jun 7, 2026 at 1:12 PM
45 15SandraNC_45, Dr.EndoIndy, tom_AK and 42 others
Reply Quote Save Share Report

Similar Threads

Prior authorization success: step-by-step guide with templates5 replies
Cigna now covering Zepbound — how I got approved13 replies
Appeal letter template — denied PA for GLP-1 medications4 replies
Mounjaro savings card — manufacturer program changes 202610 replies
Medicare Part D GLP-1 coverage — what's covered in 202610 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register